ArticleJournal for immunotherapy of cancer2026
Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model.
Geovana S F Leite et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.